Skip to main content
. 2011 Jan 3;2010:709678. doi: 10.1155/2010/709678

Table 5.

Characteristics of patients receiving Gefitinib.

Somatic Mutational Spectrum EGFR
No Age Previous Chemo-therapy Response TTP
(months)
Survival
(months)
RAS
12/13
EGFR Exons 18–21 BRAF exon 15 MET 5′–3′ exon 14 intro-exon boundaries Her2
Exon20
FISH IHC
1 38 Y PD 1.25 8.85 WT WT WT WT Y781C ND 0
2 50 Y PR 2.20 5.70 WT WT WT WT WT ND ND
3 75 Y SD 5.31 6.46 WT WT WT WT WT WT 0
4 59 Y NE 2.66 2.66 WT WT WT WT Q795R WT 3
W825X
5 63 Y SD 12.13 12.13 WT delL747-P753insS WT WT WT Amp ND
6 66 Y PD 2.07 2.43 WT WT WT WT WT WT 3
7 63 Y SD 7.74 9.54 WT delL747-P753insS WT WT WT WT 0
8 72 Y SD 8.46 11.70 WT R836R WT WT WT Amp 3
V843I
9 62 Y SD 7.84 8.03 WT WT WT WT WT ND 3
10 72 Y PR 3.11 3.11 WT WT WT WT WT WT 3
11 75 Y PD 5.15 5.15 WT WT WT WT WT Amp 2
12 66 N PR 4.10 11.64 WT WT WT WT WT Gain 2
13 74 N PD 3.57 9.15 WT WT WT WT WT WT 3
14 61 N PD 1.64 3.74 WT WT WT WT WT WT 3
15 70 N CR 15.05 17.57 G12D WT WT WT WT WT 3
16 69 Y PD 0.82 10.75 WT WT WT WT WT WT 0
17 63 Y PD 0.75 2.89 WT WT WT WT WT WT 3
18 72 Y NE 4.59 4.59 WT WT WT WT WT WT 3
19 59 Y SD 1.48 3.80 WT WT WT WT WT WT 2

Abbreviations: Y: Yes; N: No; IHC: immunohistochemistry; FISH: fluorescent in situ hybridization; ND: not determined; gain: aneuploidy; CR: complete response; PR: partial response; SD: stable disease; PR: progressive disease; NE: not evaluable.